Beilu Pharmaceutical is a leading Chinese pharmaceutical company that has been making waves in the industry. Founded in 1992, Beilu has a rich history of innovation and dedication to improving people's lives.
With a strong focus on research and development, Beilu has established itself as a pioneer in the field of pharmaceuticals. The company's commitment to quality and excellence has earned it a reputation as a trusted partner in the industry.
Beilu's products cater to a wide range of therapeutic areas, including oncology, cardiovascular, and neurological disorders. This diversified portfolio has enabled the company to reach a broad customer base and establish a strong presence in the market.
Beilu's growth and success can be attributed to its talented team of professionals who are passionate about making a difference. With a strong leadership team at the helm, the company is well-positioned for continued growth and expansion.
Take a look at this: Xi'an Aircraft Industrial Corporation
Beijing Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. has a subsidiary that has received a license to enter the Brazilian market, as reported on September 3.
The company's financial performance has been reported in various earnings results, including one for the half year ended June 30, 2025, which was announced on August 25.
Beijing Beilu Pharmaceutical Co., Ltd. has a market capitalization of 4.84B, with a P/E ratio of 207x in 2024.
Here is a list of some of the company's key financial metrics:
The company's free float is 66.69%, and its yield is 0.81% in 2024.
Products and Approvals
Beilu Pharmaceutical has a range of products, primarily focused on the pharmaceutical industry. Their main product is Jiuwei Zhenxin Granules.
Beilu Pharma also produces gadopentetate dimeglumine injections and Iohexol injections. These are crucial products for medical use.
Their products cater to a significant market, with sales exceeding 1.3 billion yuan in 2023 in public medical institutions in China. This is a testament to the demand for their products.
Beilu Pharmaceutical has received approval for registration for their compound polyethylene glycol electrolyte powder (III). This is a significant achievement for the company.
This approval further enriches the product pipeline of Beilu Pharmaceutical in the field of digestive system diseases and enhances its market competitiveness.
Industry and Market
Beilu Pharmaceutical is a leading company in the Chinese pharmaceutical industry. It was founded in 2009 and is headquartered in Shanghai.
The company specializes in the research, development, and manufacturing of innovative pharmaceutical products. This includes APIs, intermediates, and finished dosage forms.
Beilu Pharmaceutical has a strong presence in the domestic market, with a significant share of the Chinese pharmaceutical market. Its products have been widely used in hospitals and clinics across the country.
The company has a robust pipeline of products under development, with a focus on oncology, cardiovascular, and central nervous system diseases. This is a key area of growth for the company.
Beilu Pharmaceutical has established partnerships with several domestic and international companies to expand its global reach. This includes collaborations with research institutions and pharmaceutical companies.
The company has received recognition for its innovative products and business practices, including awards from the Chinese government and industry associations.
You might like: Croatian Bank for Reconstruction and Development
Financials
Beilu Pharmaceutical's financials show a significant improvement in net income, with a net income of $13.65M in 2024, up from a net loss of -$71.76M in 2023. The company's net sales also increased to $1.3B in 2024, up from $891M in 2023.
The company's net debt has increased to $2.33B in 2024, up from $521M in 2023. However, the current ratio of 2.57 in 2024 indicates a strong ability to meet short-term obligations.
Here's a breakdown of Beilu Pharmaceutical's financial performance in 2023 and 2024:
Beijing Pharmaceutical Valuation
Beijing Beilu Pharmaceutical Co., Ltd. has a capitalization of 4.84B, with a P/E ratio of -47.5x in 2023 and 207x in 2024.
The company's enterprise value is 5.03B, with an EV/Sales ratio of 3.98x in 2023 and 3.29x in 2024.
The free-float of the company is 66.69%.
Financials
Beijing Beilu Pharmaceutical Co., Ltd. has seen a significant increase in its net sales, from 891M in 2023 to 984M in 2024.
The company's net income has also shown improvement, with a net income of 13.65M in 2024 compared to a net loss of -71.76M in 2023.
Beijing Beilu Pharmaceutical Co., Ltd.'s net debt has increased from 42.28M in 2023 to 189M in 2024.
Here's a comparison of the company's financial metrics in 2023 and 2024:
The company's capitalization has also seen a significant increase, from 4.84B in 2023 to 59.69B in 2024.
Beijing Beilu Pharmaceutical Co., Ltd.'s P/E ratio has changed from -47.5x in 2023 to 207x in 2024.
The company's EV/Sales ratio has decreased from 3.98x in 2023 to 3.29x in 2024.
The Current Ratio of Beijing Beilu Pharmaceutical Co Ltd (300016.SZ) is 2.57, indicating a strong ability to meet obligations.
The company's Current Ratio has fluctuated over the years, ranging from 2.57 in 2024 to 7.15 in 2018.
Featured Images: pexels.com
